Ovoca Presents at BIO 2019 International Convention, Philadelphia
Ovoca Bio plc is pleased to announce that on 1st March 2019 its subsidiary, IVIX, was granted patent No 234753 in Israel covering any use for a large list of peptide variants based on BP-101.
Ovoca Bio plc is pleased to announce that its subsidiary IVIX has commenced the process of preparing an integrated Clinical Development Plan (“CDP”) for its investigational drug candidate, Libicore (BP-101), for both the US and EU regions with Biorasi LLC (“Biorasi”), an experienced US-based contract research organization.
|March 24, 2020||Acquisition of Remaining Minority Shareholding in IVIX LLC|
|September 16, 2019||Interim Results|
|September 12, 2019||Filing of Marketing Authorisation Application with Russian Ministry of Health for BP-101|
|June 28, 2019||Annual Report 2018|
|May 25, 2018||Annual Report 2017|
|June 30, 2017||Annual Report 2016|
|November 20, 2019||Ovoca Bio plc BP-101 Presentation|
|March 29, 2019||Ovoca Bio plc | Libicore Presentation|
|July 27, 2018||Ovoca Bio plc | Libicore Presentation|